



Europäisches
Patentamt

European
Patent Office

~~Wordmark~~
Office européen
des brevets

PCT/EP03/07066

08 MAR 2005

REC'D 27 AUG 2003

WIPO

PCT

Bescheinigung

Certificate

Attestation

Die angehefteten Unterla-
gen stimmen mit der
ursprünglich eingereichten
Fassung der auf dem näch-
sten Blatt bezeichneten
europäischen Patentanmel-
dung überein.

The attached documents
are exact copies of the
European patent application
described on the following
page, as originally filed.

Les documents fixés à
cette attestation sont
conformes à la version
initialement déposée de
la demande de brevet
européen spécifiée à la
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

02020256.0

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamts;
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets
p.o.

R C van Dijk

BEST AVAILABLE COPY





Anmeldung Nr:
Application no.: 02020256.0
Demande no:

Anmeldetag:
Date of filing: 10.09.02
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

LION Bioscience AG
Im Neuenheimer Feld 517
69120 Heidelberg
ALLEMAGNE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.
If no title is shown please refer to the description.
Si aucun titre n'est indiqué se référer à la description.)

NR3B1 nuclear receptor binding compounds

In Anspruch genommene Priorität(en) / Priority(ies) claimed /Priorité(s)
revendiquée(s)
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/
Classification internationale des brevets:

G07D231/00

Am Anmeldetag benannte Vertragsstaaten/Contracting states designated at date of
filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

NR3B1 Nuclear Receptor Binding Compounds

The present invention relates to compounds according to the general formula (1) which bind to the NR3B1 receptor and act as antagonists or agonists of the NR3B1 receptor. The invention further relates to the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and the production of medicaments using said compounds.

BACKGROUND OF THE INVENTION

Multicellular organisms are dependent on advanced mechanisms of information transfer between cells and body compartments. The information that is transmitted can be highly complex and can result in the alteration of genetic programs involved in cellular differentiation, proliferation, or reproduction. The signals, or hormones, are often simple molecules, such as peptides, fatty acid, or cholesterol derivatives.

Many of these signals produce their effects by ultimately changing the transcription of specific genes. One well-studied group of proteins that mediate a cell's response to a variety of signals is the family of transcription factors known as nuclear receptors, hereinafter referred to often as "NR". Members of this group include receptors for steroid hormones, vitamin D, ecdysone, cis and trans retinoic acid, thyroid hormone, bile acids, cholesterol-derivatives, fatty acids (and other peroxisomal proliferators), as well as so-called orphan receptors, proteins that are structurally similar to other members of this group, but for which no ligands are known (Escriva, H. et al., Ligand binding was acquired during evolution of nuclear receptors, PNAS, 94, 6803 – 6808, 1997). Orphan receptors may be indicative of unknown signalling pathways in the cell or may be nuclear receptors that function without ligand activation. The activation of transcription by some of these orphan receptors may occur in the absence of an exogenous ligand and/or through signal transduction pathways originating from the cell surface (Mangelsdorf, D. J. et al., The nuclear receptor superfamily: the second decade, Cell 83, 835-839, 1995).

In general, three functional domains have been defined in NRs. An amino terminal domain is believed to have some regulatory function. A DNA-binding domain hereinafter referred to as

"DBD" usually comprises two zinc finger elements and recognises a specific Hormone Responsive Element hereinafter referred to as "HRE" within the promoters of responsive genes. Specific amino acid residues in the "DBD" have been shown to confer DNA sequence binding specificity (Schena, M. & Yamamoto, K.R., Mammalian Glucocorticoid Receptor Derivatives Enhance Transcription in Yeast, *Science*, 241:965-967, 1988). A Ligand-binding-domain hereinafter referred to as "LBD" is at the carboxy-terminal region of known NRs. In the absence of hormone, the LBD appears to interfere with the interaction of the DBD with its HRE. Hormone binding seems to result in a conformational change in the NR and thus opens this interference (Brzozowski et al., Molecular basis of agonism and antagonism in the oestrogen receptor, *Nature*, 389, 753 – 758, 1997; Wagner et al., A structural role for hormone in the thyroid hormone receptor, *Nature*, 378, 690 – 697, 1995). A NR without the HBD constitutively activates transcription but at a low level.

Coactivators or transcriptional activators are proposed to bridge between sequence specific transcription factors, the basal transcription machinery and in addition to influence the chromatin structure of a target cell. Several proteins like SRC-1, ACTR, and Grip1 interact with NRs in a ligand enhanced manner (Heery et al., A signature motif in transcriptional coactivators mediates binding to nuclear receptors, *Nature*, 387, 733 – 736; Heinzl et al., A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression, *Nature* 387, 43 – 47, 1997). Furthermore, the physical interaction with negative receptor-interacting proteins or corepressors has been demonstrated (Xu et al., Coactivator and Corepressor complexes in nuclear receptor function, *Curr Opin Genet Dev*, 9 (2), 140 – 147, 1999).

Nuclear receptor modulators like steroid hormones affect the growth and function of specific cells by binding to intracellular receptors and forming nuclear receptor-ligand complexes. Nuclear receptor-hormone complexes then interact with a hormone response element (HRE) in the control region of specific genes and alter specific gene expression.

The Estrogen Related Receptor (ERR) alpha, beta and gamma (hereinafter referred to as NR3B1, NR3B2 and NR3B3 when referring to the human receptor) are nuclear receptors which activate genes upon binding to the promoter region of target genes either in a homodimeric or monomeric fashion or as a heterodimer with the estrogen receptor alpha. NR3B1 and NR3B2 were the first orphan nuclear receptors identified more than a decade ago (Giguere, et al. 1988 *Nature* 331, 91-94). Although the ERR's display high homology to the estrogen re-

ceptor (ER) they do not bind or respond to natural occurring estrogens. The ERR's are structurally and functionally related to the ERa and ERb and have been shown to possess the potential to positively and negatively regulate estrogen regulated gene networks (Vanacker, JM et al 1999 EMBO J. 18, 4270-4279).

The ERR's are described as constitutive activators of transcription. They contain a well conserved AF-2 domain that is necessary for the constitutive transcriptional activity. The interaction of the ERR's with cofactors (e.g. GRIP-1, SRC-1, ACTR) is ligand independent. Nevertheless, the observation that the constitutive activity depends on a factor present in serum that can be withdrawn gives a hint, that there may exist also agonistic ligands for the ERR's that can induce their activity.

To date no physiological ligands have been identified for ERRa (NR3B1) although in very recent publications, Diethylstilbestrol was identified as a synthetic substance able to bind to and inhibit the constitutive activity of ERRa but also ERRb and ERRg (Tremblay, G.B. 2001 Genes & Development 15, 833-838).

To date only very few compounds have been described which bind the NR3B1 receptor and thus show utility for treating diseases or conditions which are due to or are influenced by said nuclear receptor (Maloney et al., J Med Chem, 10; 43(16):2971-4, 2000).

It was thus an object of the present invention to provide for novel NR3B1 binding compounds. It was thus an object of the present invention to provide for compounds which by means of binding the NR3B1 receptor act as antagonist or agonist of said receptor and thus show utility for treating diseases or conditions which are due to or influenced by said nuclear receptor.

It was further an object of the invention to provide for compounds which may be used for the manufacture of a medicament for the treatment of conditions or diseases like cancer, osteoporosis, obesity, lipid disorders, cardiovascular disorders or fertility and reproductive health associated conditions or diseases. In a preferred embodiment of the invention it was an object of the invention to provide for compounds for the manufacture of anti-tumour medicaments.

SUMMARY OF THE INVENTION

The present invention provides, *inter alia*, novel NR3B1 nuclear receptor protein binding compounds according to the general formula (1) shown below. Said compounds are also binders of mammalian homologues of said receptor. Further the object of the invention was solved by providing for amongst the NR3B1 nuclear receptor protein binding compounds according to the general formula (1) such compounds which act as antagonists and such compounds which act as agonists of the human ERRa receptor or a mammalian homologue thereof.


The invention provides for ERRa antagonists or agonists which may be used for the manufacture of a medicament for the treatment of cancer, osteoporosis, obesity, lipid disorders or a cardiovascular disorder or fertility and reproductive health associated conditions or diseases. In a preferred embodiment of the invention the compounds according to the invention may be used for manufacture of anti-tumour medicaments and/or for the treatment of diseases such as cancer.

The foregoing merely summarises certain aspects of the present invention and is not intended, nor should it be construed, to limit the invention in any manner. All patents and other publications recited herein are hereby incorporated by reference in their entirety.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The invention provides for a compound according to formula (1), or pharmaceutical acceptable salts or solvates thereof, hereinafter also referred to as the "compounds according to the invention" including particular and preferred embodiments thereof,

formula (1)



wherein in formula (1) as shown above,

R₁ is phenyl, substituted phenyl, C₅ to C₆ heteroaryl, C₅ to C₆ substituted heteroaryl, naphthyl or substituted naphthyl,

R₂ is H, C₁ to C₈ alkyl, C₁ to C₇ acyl or C₁ to C₇ substituted acyl, C₁ to C₈ substituted alkyl, C₇ to C₁₂ alkylphenyl or C₇ to C₁₂ substituted phenylalkyl, C₃ to C₈ cycloalkyl, C₃ to C₈ substituted cycloalkyl, C₅ to C₆ heteroaryl, [C₅ to C₆]-heteroaryl-(C₁ to C₆)-alkyl, and

R₃ is H, C₁ to C₈ alkyl, C₁ to C₈ substituted alkyl, C₇ to C₁₂ alkylphenyl or C₇ to C₁₂ substituted phenylalkyl, halogen, C₁ to C₈ alkoxy, furanyl, substituted furanyl, thiazyl, substituted thiazyl, carboxy, ester, amide or C₁ to C₈ aminoacyl.

The inventors have unexpectedly identified the compounds as well as the general structure capable of effectively binding ERRa and as claimed in the present invention amongst approximately 4500 compounds that were within a compound library that was not previously disclosed

The compounds of the invention can also exist as solvates and hydrates. Thus, these compounds may crystallise with, for example, waters of hydration, or one, a number of, or any fraction thereof of molecules of the mother liquor solvent. The solvates and hydrates of such compounds are included within the scope of this invention.

The term "halogen" refers to the fluoro, chloro, bromo or iodo atoms. There can be one or more halogen, which are the same or different. Preferred halogens are chloro and fluoro.

The symbol "H" denotes a hydrogen atom.

The term "C₁ to C₇ acyl" encompasses groups such as formyl, acetyl, propionyl, butyryl, pentanoyl, pivaloyl, hexanoyl, heptanoyl, benzoyl and the like. Preferred acyl groups are acetyl and benzoyl.

The term "C₁ to C₇ substituted acyl" denotes the acyl group substituted by one or more, and preferably one or two, halogen, hydroxy, protected hydroxy, oxo, protected oxo, cyclohexyl, naphthyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, guanidino, heterocyclic ring, substituted heterocyclic ring, imidazolyl, indolyl, pyrrolidinyl, C₁ to C₇ alkoxy, C₁ to C₇ acyl, C₁ to C₇ acyloxy, nitro, C₁ to

C₆ alkyl ester, carboxy, protected carboxy, carbamoyl, carboxamide, protected carboxamide, N-(C₁ to C₆ alkyl)carboxamide, protected N-(C₁ to C₆ alkyl)carboxamide, N,N-di(C₁ to C₆ alkyl)carboxamide, cyano, methylsulfonylamino, thiol, C₁ to C₄ alkylthio or C₁ to C₄ alkylsulfonyl groups. The substituted acyl groups may be substituted once or more, and preferably once or twice, with the same or with different substituents.

Examples of C₁ to C₇ substituted acyl groups include 4-phenylbutyroyl, 3-phenylbutyroyl, 3-phenylpropanoyl, 2-cyclohexanylacetyl, cyclohexanecarbonyl, 2-furanoyl and 3-dimethylaminobenzoyl and the like.

The term "substituted phenyl" specifies a phenyl group substituted with one or more, and preferably one or two, moieties chosen from the groups consisting of halogen, hydroxy, protected hydroxy, cyano, nitro, C₁ to C₆ alkyl, C₁ to C₆ substituted alkyl, C₁ to C₇ alkoxy, C₁ to C₇ substituted alkoxy, C₁ to C₇ acyl, C₁ to C₇ substituted acyl, C₁ to C₇ acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, carboxamide, protected carboxamide, N-(C₁ to C₆ alkyl)carboxamide, protected N-(C₁ to C₆ alkyl)carboxamide, N, N-di(C₁ to C₆ alkyl)carboxamide, trifluoromethyl, N-((C₁ to C₆ alkyl)sulfonyl)amino, N-(phenylsulfonyl)amino or phenyl, wherein the phenyl is substituted or unsubstituted, such that, for example, a biphenyl results.

Examples of the term "substituted phenyl" includes a mono- or di(halo)phenyl group such as 2, 3 or 4-chlorophenyl, 2,6-dichlorophenyl, 2,5-dichlorophenyl, 3,4-dichlorophenyl, 2, 3 or 4-bromophenyl, 3,4-dibromophenyl, 3-chloro-4-fluorophenyl, 2, 3 or 4-fluorophenyl and the like; a mono or di(hydroxy)phenyl group such as 2, 3 or 4-hydroxyphenyl, 2,4-dihydroxyphenyl, the protected-hydroxy derivatives thereof and the like; a nitrophenyl group such as 2, 3 or 4-nitrophenyl; a cyanophenyl group, for example, 2, 3 or 4-cyanophenyl; a mono- or di(alkyl)phenyl group such as 2, 3 or 4-methylphenyl, 2,4-dimethylphenyl, 2, 3 or 4-(iso-propyl)phenyl, 2, 3 or 4-ethylphenyl, 2, 3 or 4-(n-propyl)phenyl and the like; a mono or di(alkoxyl)phenyl group, for example, 2,6-dimethoxyphenyl, 2, 3 or 4-methoxyphenyl, 2, 3 or 4-ethoxyphenyl, 2, 3 or 4-(isopropoxy)phenyl, 2, 3 or 4-(t-butoxy)phenyl, 3-ethoxy-4-methoxyphenyl and the like; 2, 3 or 4-trifluoromethylphenyl; a mono- or dicarboxyphenyl or (protected carboxy)phenyl group

such as 2, 3 or 4-carboxyphenyl or 2,4-di(protected carboxy)phenyl; a mono- or di(hydroxymethyl)phenyl or (protected hydroxymethyl)phenyl such as 2, 3, or 4-(protected hydroxymethyl)phenyl or 3,4-di(hydroxymethyl)phenyl; a mono- or di(aminomethyl)phenyl or (protected aminomethyl)phenyl such as 2, 3 or 4-(aminomethyl)phenyl or 2,4-(protected aminomethyl)phenyl; or a mono- or di(N-(methylsulfonylamino))phenyl such as 2, 3 or 4-(N-(methylsulfonylamino))phenyl. Also, the term "substituted phenyl" represents disubstituted phenyl groups wherein the substituents are different, for example, 3-methyl-4-hydroxyphenyl, 3-chloro-4-hydroxyphenyl, 2-methoxy-4-bromophenyl, 4-ethyl-2-hydroxyphenyl, 3-hydroxy-4-nitrophenyl, 2-hydroxy 4-chlorophenyl and the like.

The term "heteroaryl" means a heterocyclic aromatic derivative which is a five-membered or six-membered ring system having from 1 to 4 heteroatoms, such as oxygen, sulfur and/or nitrogen, in particular nitrogen, either alone or in conjunction with sulfur or oxygen ring atoms. Examples of heteroaryls include pyridinyl, pyrimidinyl, and pyrazinyl, pyridazinyl, pyrrolo, furano, thiopheno, oxazolo, isoxazolo, phthalimido, thiazolo and the like.

The term "substituted heteroaryl" means the above-described heteroaryl is substituted with, for example, one or more, and preferably one or two, substituents which are the same or different which substituents can be halogen, hydroxy, protected hydroxy, cyano, nitro, C₁ to C₆ alkyl, C₁ to C₇ alkoxy, C₁ to C₇ substituted alkoxy, C₁ to C₇ acyl, C₁ to C₇ substituted acyl, C₁ to C₇ acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, carboxamide, protected carboxamide, N-(C₁ to C₆ alkyl)carboxamide, protected N-(C₁ to C₆ alkyl)carboxamide, N, N-di(C₁ to C₆ alkyl)carboxamide, trifluoromethyl, N-((C₁ to C₆ alkyl)sulfonyl)amino or N-(phenylsulfonyl)amino groups.

The term "substituted naphthyl" specifies a naphthyl group substituted with one or more, and preferably one or two, moieties either on the same ring or on different rings chosen from the groups consisting of halogen, hydroxy, protected hydroxy, cyano, nitro, C₁ to C₆ alkyl, C₁ to C₇ alkoxy, C₁ to C₇ acyl, C₁ to C₇ acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, carboxamide, protected carboxamide, N-(C₁ to C₆ alkyl)carboxamide, protected N-(C₁ to C₆ al-

kyl)carboxamide, N, N-di(C₁ to C₆ alkyl)carboxamide, trifluoromethyl, N-((C₁ to C₆ alkyl)sulfonyl)amino or N-(phenylsulfonyl)amino.

Examples of the term "substituted naphthyl" includes a mono or di(halo)naphthyl group such as 1, 2, 3, 4, 5, 6, 7 or 8-chloronaphthyl, 2, 6-dichloronaphthyl, 2, 5-dichloronaphthyl, 3, 4-dichloronaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-bromonaphthyl, 3, 4-dibromonaphthyl, 3-chloro-4-fluoronaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-fluoronaphthyl and the like; a mono or di(hydroxy)naphthyl group such as 1, 2, 3, 4, 5, 6, 7 or 8-hydroxynaphthyl, 2, 4-dihydroxynaphthyl, the protected-hydroxy derivatives thereof and the like; a nitronaphthyl group such as 3- or 4-nitronaphthyl; a cyanonaphthyl group, for example, 1, 2, 3, 4, 5, 6, 7 or 8-cyanonaphthyl; a mono- or di(alkyl)naphthyl group such as 2, 3, 4, 5, 6, 7 or 8-methylnaphthyl, 1, 2, 4-dimethylnaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-(isopropyl)naphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-ethylnaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-(n-propyl)naphthyl and the like; a mono or di(alkoxy)naphthyl group, for example, 2, 6-dimethoxynaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-methoxynaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-ethoxynaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-(isopropoxy)naphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-(t-butoxy)naphthyl, 3-ethoxy-4-methoxynaphthyl and the like; 1, 2, 3, 4, 5, 6, 7 or 8-trifluoromethylnaphthyl; a mono- or dicarboxynaphthyl or (protected carboxy)naphthyl group such as 1, 2, 3, 4, 5, 6, 7 or 8-carboxynaphthyl or 2, 4-di-(protected carboxy)naphthyl; a mono- or di(hydroxymethyl)naphthyl or (protected hydroxymethyl)naphthyl such as 1, 2, 3, 4, 5, 6, 7 or 8-(protected hydroxymethyl)naphthyl or 3, 4-di(hydroxymethyl)naphthyl; a mono- or di(amino)naphthyl or (protected amino)naphthyl such as 1, 2, 3, 4, 5, 6, 7 or 8-(amino)naphthyl or 2, 4-(protected amino)-naphthyl, a mono- or di(aminomethyl)naphthyl or (protected aminomethyl)naphthyl such as 2, 3, or 4-(aminomethyl)naphthyl or 2, 4-(protected aminomethyl)-naphthyl; or a mono- or di(N-methylsulfonylamino) naphthyl such as 1, 2, 3, 4, 5, 6, 7 or 8-(N-methylsulfonylamino)naphthyl. Also, the term "substituted naphthyl" represents disubstituted naphthyl groups wherein the substituents are different, for example, 3-methyl-4-hydroxynaphth-1-yl, 3-chloro-4-hydroxynaphth-2-yl, 2-methoxy-4-bromonaphth-1-yl, 4-ethyl-2-hydroxynaphth-1-yl, 3-hydroxy-4-nitronaphth-2-yl, 2-hydroxy-4-chloronaphth-1-yl, 2-methoxy-7-bromonaphth-1-yl, 4-ethyl-5-hydroxynaphth-2-yl, 3-hydroxy-8-nitronaphth-2-yl, 2-hydroxy-5-chloronaphth-1-yl and the like.

The term "C₁ to C₈ alkyl" denotes such radicals as methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, amyl, tert-amyl, hexyl, n-heptyl, 2-heptyl, 3-heptyl, 4-heptyl, 2-methyl-1-hexyl, 2-methyl-2-hexyl, 2-methyl-3-hexyl, n-octyl and the like.

The term "C₁ to C₈ substituted alkyl" denotes that the above C₁ to C₈ alkyl groups are substituted by one or more, and preferably one or two, halogen, hydroxy, protected hydroxy, oxo, protected oxo, C₃ to C₇ cycloalkyl, naphthyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, guanidino, protected guanidino, heterocyclic ring, substituted heterocyclic ring, imidazolyl, indolyl, pyrrolidinyl, C₁ to C₇ alkoxy, C₁ to C₇ acyl, C₁ to C₇ acyloxy, nitro, carboxy, protected carboxy, carbamoyl, carboxamide, protected carboxamide, N-(C₁ to C₆ alkyl)carboxamide, protected N-(C₁ to C₆ alkyl)carboxamide, N,N-di(C₁ to C₆ alkyl)carboxamide, cyano, methylsulfonylamino, thiol, C₁ to C₄ alkylthio or C₁ to C₄ alkylsulfonyl groups. The substituted alkyl groups may be substituted once or more, and preferably once or twice, with the same or with different substituents.

Examples of the above substituted alkyl groups include the 2-oxo-prop-1-yl, 3-oxo-but-1-yl, cyanomethyl, nitromethyl, chloromethyl, hydroxymethyl, tetrahydropyranyloxymethyl, trityloxymethyl, propionyloxymethyl, amino, methylamino, aminomethyl, dimethylamino, carboxymethyl, allyloxycarbonylmethyl, allyloxycarbonylaminomethyl, methoxymethyl, ethoxymethyl, t-butoxymethyl, acetoxymethyl, chloromethyl, bromomethyl, iodomethyl, trifluoromethyl, 6-hydroxyhexyl, 2,4-dichloro(n-butyl), 2-aminopropyl, 1-chloroethyl, 2-chloroethyl, 1-bromoethyl, 2-chloroethyl, 1-fluoroethyl, 2-fluoroethyl, 1-iodoethyl, 2-iodoethyl, 1-chloropropyl, 2-chloropropyl, 3-chloropropyl, 1-bromopropyl, 2-bromopropyl, 3-bromopropyl, 1-fluoropropyl, 2-fluoropropyl, 3-fluoropropyl, 1-iodopropyl, 2-iodopropyl, 3-iodopropyl, 2-aminoethyl, 1-aminoethyl, N-benzoyl-2-aminoethyl, N-acetyl-2-aminoethyl, N-benzoyl-1-aminoethyl, N-acetyl-1-aminoethyl and the like.

The term "C₇ to C₁₂ phenylalkyl" denotes a C₁ to C₆ alkyl group substituted at any position by a phenyl, substituted phenyl, heteroaryl or substituted heteroaryl. Examples of such a group include benzyl, 2-phenylethyl, 3-phenyl(n-propyl), 4-phenylhexyl, 3-phenyl(n-amyl), 3-phenyl(sec-butyl) and the like. Preferred C₇ to C₁₂ phenylalkyl groups are the benzyl and the phenylethyl groups.

The term "C₇ to C₁₂ substituted phenylalkyl" denotes a C₇ to C₁₂ phenylalkyl group substituted on the C₁ to C₆ alkyl portion with one or more, and preferably one or two, groups chosen from halogen, hydroxy, protected hydroxy, oxo, protected oxo, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, guanidino, protected guanidino, heterocyclic ring, substituted heterocyclic ring, C₁ to C₆ alkyl, C₁ to C₆ substituted alkyl, C₁ to C₇ alkoxy, C₁ to C₇ substituted alkoxy, C₁ to C₇ acyl, C₁ to C₇ substituted acyl, C₁ to C₇ acyloxy, nitro, carboxy, protected carboxy, carbamoyl, carboxamide, protected carboxamide, N-(C₁ to C₆ alkyl)carboxamide, protected N-(C₁ to C₆ alkyl)carboxamide, N, N-(C₁ to C₆ dialkyl)carboxamide, cyano, N-(C₁ to C₆ alkylsulfonyl)amino, thiol, C₁ to C₄ alkylthio, C₁ to C₄ alkylsulfonyl groups; and/or the phenyl group may be substituted with one or more, and preferably one or two, substituents chosen from halogen, hydroxy, protected hydroxy, cyano, nitro, C₁ to C₆ alkyl, C₁ to C₆ substituted alkyl, C₁ to C₇ alkoxy, C₁ to C₇ substituted alkoxy, C₁ to C₇ acyl, C₁ to C₇ substituted acyl, C₁ to C₇ acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, carboxamide, protected carboxamide, N-(C₁ to C₆ alkyl) carboxamide, protected N-(C₁ to C₆ alkyl) carboxamide, N, N-di(C₁ to C₆ alkyl)carboxamide, trifluoromethyl, N-((C₁ to C₆ alkyl)sulfonyl)amino, N-(phenylsulfonyl)amino, cyclic C₂ to C₇ alkylene or a phenyl group, substituted or unsubstituted, for a resulting biphenyl group. The substituted alkyl or phenyl groups may be substituted with one or more, and preferably one or two, substituents which can be the same or different.

Examples of the term "C₇ to C₁₂ substituted phenylalkyl" include groups such as 2-phenyl-1-chloroethyl, 2-(4-methoxyphenyl)ethyl, 4-(2,6-dihydroxy phenyl)n-hexyl, 2-(5-cyano-3-methoxyphenyl)n-pentyl, 3-(2,6-dimethylphenyl)n-propyl, 4-chloro-3-aminobenzyl, 6-(4-methoxyphenyl)-3-carboxy(n-hexyl), 5-(4-aminomethylphenyl)- 3-(aminomethyl)n-pentyl, 5-phenyl-3-oxo-n-pent-1-yl and the like.

The term "heterocycle" or "heterocyclic ring" denotes optionally substituted three-membered to eight-membered rings that have 1 to 4 heteroatoms, such as oxygen, sulfur and/or nitrogen, in particular nitrogen, either alone or in conjunction with sulfur or oxygen ring atoms. These three-membered to eight-membered rings may be saturated, fully unsaturated or partially unsaturated, with fully saturated rings being preferred. Preferred heterocyclic rings include mor-

pholino, piperidiny, piperaziny, 2-amino-imidazo, tetrahydrofurano, pyrrolo, tetrahydrothiophen-yl, hexylmethylenimine and heptylmethylenimine.

The term "substituted heterocycle" or "substituted heterocyclic ring" means the above-described heterocyclic ring is substituted with, for example, one or more, and preferably one or two, substituents which are the same or different which substituents can be halogen, hydroxy, protected hydroxy, oxo, protected oxo, cyano, nitro, C₁ to C₁₂ alkyl, C₁ to C₁₂ alkoxy, C₁ to C₁₂ substituted alkoxy, C₁ to C₁₂ acyl, C₁ to C₁₂ acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino carboxamide, protected carboxamide, N-(C₁ to C₁₂ alkyl)carboxamide, protected N-(C₁ to C₁₂ alkyl)carboxamide, N, N-di(C₁ to C₁₂ alkyl)carboxamide, trifluoromethyl, N-((C₁ to C₁₂ alkyl)sulfonyl)amino, N-(phenylsulfonyl)amino, heterocycle or substituted heterocycle groups.

The term "C₁ to C₈ alkoxy" as used herein denotes groups such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, t-butoxy and like groups. A preferred alkoxy is methoxy. The term "C₁ to C₈ substituted alkoxy" means the alkyl portion of the alkoxy can be substituted in the same manner as in relation to C₁ to C₈ substituted alkyl. [Please check carefully...]

The term "C₁ to C₈ aminoacyl" encompasses groups such as formyl, acetyl, propionyl, butyryl, pentanoyl, pivaloyl, hexanoyl, heptanoyl, octanoyl, benzoyl and the like attached to a nitrogen moiety.

The term "C₁ to C₈ substituted aminoacyl" denotes the acyl group, attached to a nitrogen moiety, substituted by one or more, and preferably one or two, halogen, hydroxy, protected hydroxy, oxo, protected oxo, cyclohexyl, naphthyl, amino, protected amino, (monosubstituted)amino, protected (monosubstituted)amino, (disubstituted)amino, guanidino, heterocyclic ring, substituted heterocyclic ring, imidazolyl, indolyl, pyrrolidinyl, C₁ to C₁₂ alkoxy, C₁ to C₁₂ acyl, C₁ to C₁₂ acyloxy, nitro, C₁ to C₁₂ alkyl ester, carboxy, protected carboxy, carbamoyl, carboxamide, protected carboxamide, N-(C₁ to C₁₂ alkyl)carboxamide, protected N-(C₁ to C₁₂ alkyl)carboxamide, N,N-di(C₁ to C₁₂ alkyl)carboxamide, cyano, methylsulfonylamino, thiol, C₁ to C₁₀ alkylthio or C₁ to C₁₀ alkylsulfonyl groups. The substituted acyl groups

may be substituted once or more, and preferably once or twice, with the same or with different substituents.

Examples of C_1 to C_8 substituted acyl groups include 4-phenylbutyroyl, 3-phenylbutyroyl, 3-phenylpropanoyl, 2-cyclohexanylacetyl, cyclohexanecarbonyl, 2-furanoyl and 3-dimethylaminobenzoyl.

This invention provides a pharmaceutical composition comprising an effective amount of a compound according to the invention. Such compounds can be administered by various routes, for example oral, subcutaneous, intramuscular, intravenous or intracerebral. The preferred route of administration would be oral at daily doses of the compound for adult human treatment of about 0.01 -5000 mg, preferably 1-1500 mg per day. The appropriate dose may be administered in a single dose or as divided doses presented at appropriate intervals for example as two, three four or more subdoses per day.

For preparing pharmaceutical compositions containing compounds of the invention, inert, pharmaceutically acceptable carriers are used. The pharmaceutical carrier can be either solid or liquid. Solid form preparations include, for example, powders, tablets, dispersible granules, capsules, cachets, and suppositories.

A solid carrier can be one or more substances which can also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents; it can also be an encapsulating material.

In powders, the carrier is generally a finely divided solid which is in a mixture with the finely divided active component. In tablets, the active compound is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.

For preparing pharmaceutical composition in the form of suppositories, a low-melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture is then poured into convenient-sized molds and allowed to cool and solidify.

Powders and tablets preferably contain between about 5% to about 70% by weight of the active ingredient. Suitable carriers include, for example, magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter and the like.


The pharmaceutical compositions can include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component (with or without other carriers) is surrounded by a carrier, which is thus in association with it. In a similar manner, cachets are also included. Tablets, powders, cachets, and capsules can be used as solid dosage forms suitable for oral administration.

Liquid pharmaceutical compositions include, for example, solutions suitable for oral or parenteral administration, or suspensions, and emulsions suitable for oral administration. Sterile water solutions of the active component or sterile solutions of the active component in solvents comprising water, ethanol, or propylene glycol are examples of liquid compositions suitable for parenteral administration.

Sterile solutions can be prepared by dissolving the active component in the desired solvent system, and then passing the resulting solution through a membrane filter to sterilise it or, alternatively, by dissolving the sterile compound in a previously sterilised solvent under sterile conditions.


In one embodiment of the present invention a compound is provided according to formula (2) below, or pharmaceutically acceptable salts or solvates thereof, wherein R_2 is H, C_1 to C_8 alkyl, C_1 to C_8 substituted alkyl, C_7 to C_{12} alkylphenyl or C_7 to C_{12} substituted phenylalkyl, R_4 is H, C_1 to C_8 alkyl, halogen, C_1 to C_8 alkoxy, carboxy, ester, amide or C_1 to C_8 aminoacyl, and R_5 is H, C_1 to C_8 alkyl, halogen, C_1 to C_8 alkoxy, carboxy, ester, amide or C_1 to C_8 aminoacyl.

formula (2)




In a preferred embodiment of the invention a compound which may act as an antagonist of NR3B1 according to formula (3) is provided, or pharmaceutical acceptable salts or solvates thereof, wherein R_2 is H, C_1 to C_7 acyl or C_1 to C_7 substituted acyl, phenyl, substituted phenyl, C_5 to C_6 heteroaryl, C_5 to C_6 substituted heteroaryl, naphthyl or substituted naphthyl, and R_6 is H, C_1 to C_8 alkyl, C_1 to C_8 substituted alkyl, C_7 to C_{12} alkylphenyl or C_7 to C_{12} substituted phenylalkyl, carboxy, ester, amide or C_1 to C_8 aminoacyl.

Formula (3)




An other preferred compound which may act as an antagonist of NR3B1 is shown in formula (4) below. The inventors have been able to demonstrate that the compound according to formula (4), wherein R_2 is H, C_1 to C_7 acyl or C_1 to C_7 substituted acyl, phenyl, substituted phenyl, C_5 to C_6 heteroaryl, C_5 to C_6 substituted heteroaryl, naphthyl or substituted naphthyl, and R_6 is H, C_1 to C_8 alkyl, C_1 to C_8 substituted alkyl, C_7 to C_{12} alkylphenyl or C_7 to C_{12} substituted phenylalkyl, carboxy, ester, amide or C_1 to C_8 aminoacyl has a low effective concentration at NR3B1 with an EC_{50} of xxx μ M wherein the EC_{50} reflects the half-maximal effective concentration, and which is higher than the EC_{50} of 1 μ M for the published ERR antagonist DES (Tremblay GB et al., Genes & Development 15, 833-838, 2001).

formula (4)




The inventors have also found the compounds according to formula (5 and 6) (shown below) to be active as antagonist of the NR3B1 human nuclear receptor (see figures for details).

formula (5) (MOLNAME 1732)



formula (6) (MOLNAME 7831)



The present invention relates to a compound as described above wherein said compounds is capable of binding the NR3B1 receptor protein or a portion thereof according to SEQ ID NO. 1 (cf. Fig. 3 A to D) or a mammalian homologue thereof. The claimed compound can bind to the NR3B1 receptor protein or a portion thereof in a mixture comprising 10-200 ng of NR3B1

receptor protein or a portion thereof, preferably the ligand binding domain, 20 mM Tris /HCl at pH 7.9; 60 mM KCl; 5 mM MgCl₂; 160ng/μl BSA in a total volume of preferably about 25 μl.

“A mammalian receptor protein homologue” of the protein according to SEQ ID NO. 1 as used herein is a protein that performs substantially the same task as NR3B1 does in humans and shares at least 40% sequence identity at the amino acid level, preferably 50 % sequence identity at the amino acid level more preferably 65 % sequence identity at the amino acid level, even more preferably 75 % sequence identity at the amino acid level and most preferably over 85 % sequence identity at the amino acid level.

The invention in particular relates to a method for prevention or treatment of a NR3B1 receptor protein or NR3B1 receptor protein homologue mediated disease or condition in a mammal comprising administration of a therapeutically effective amount of a compound according to the invention wherein the prevention or treatment is directly or indirectly accomplished through the binding of a compound according to the invention to the NR3B1 receptor protein or to the NR3B1 receptor protein homologue.

The term “mediated” herein means that the physiological pathway in which the NR3B1 receptor protein acts is either directly or indirectly involved in the disease or condition to be treated or prevented. In the case where it is indirectly involved it could be that, e.g. modulating the activity of NR3B1 by a compound according to the invention influences a parameter which has a beneficial effect on a disease or a condition. One such example is that modulation of NR3B1 activity leads to decreased levels of aromatase levels which in turn have a beneficial effect on the prevention and treatment of mammary cancer. Herein a condition is a physiological or phenotypic state which is desirably altered. One such example would be obesity which is not necessarily medically harmful but nonetheless a non desirable phenotypic condition. In a preferred embodiment of the invention the method for prevention or treatment of a NR3B1 receptor protein mediated disease or condition is applied to a human. This may be male or female.

Pharmaceutical compositions generally are administered in an amount effective for treatment or prophylaxis of a specific condition or conditions. Initial dosing in human is accompanied by clinical monitoring of symptoms, such symptoms for the selected condition. In general, the

compositions are administered in an amount of active agent of at least about 100 µg/kg body weight. In most cases they will be administered in one or more doses in an amount not in excess of about 20 mg/kg body weight per day. Preferably, in most cases, doses is from about 100 µg/kg to about 5 mg/kg body weight, daily.

For administration particularly to mammals, and particularly humans, it is expected that the daily dosage level of active agent will be 0,1 mg/kg to 10 mg/kg and typically around 1 mg/kg.

By "therapeutically effective amount" is meant a symptom- alleviating or symptom -reducing amount, a cholesterol-reducing amount, a fatty acid absorption blocking amount, a protein and/or carbohydrate digestion-blocking amount, a MCAD modulating amount or a thyroid receptor modulating amount or a osteopontin modulating amount and/or a aromatase modulating amount of a compound according to the invention.

The Estrogen receptor related receptor alpha is a nuclear receptor which modulates genes upon binding to the promoter region of target genes in a homodimeric or monomeric fashion or as heterodimers with the ERα. The relevant physiological ligands of NR3B1 are unknown. The present compounds according to the invention have been demonstrated to have a high binding efficacy [binding coefficients measured as IC50 in the range 1 to 10µM] as well as antagonistic and / or agonistic properties. Consequently they may be applied to regulate genes that participate in estrogen regulated gene networks as well as other downstream regulated genes. Examples of such genes are Lactoferrin, MCAD, Aromatase, PS2 and SHP and the function of such genes is associated but not limited to cancer, osteogenesis, obesity, energy metabolism, lipid absorption, cholesterol biosynthesis, cholesterol transport or binding, bile acid transport or binding, proteolysis, amino acid metabolism, glucose biosynthesis, protein translation, electron transport, and hepatic fatty acid metabolism. The ERR's often function in vivo as homodimers or as monomers. Published ERR antagonists such as the DES (See figure 5) are known to influence the regulation of various genes. Genes found to be regulated by DES can be found in figure 6. Thus, the invention also concerns a method of modulating a gene whose expression is regulated by the NR3B1 receptor in a mammal comprising administration of a therapeutically effective amount of a compound according to the invention to said mammal.

It is known that the orphan receptor ERR α can bind the response element of the aromatase gene (Yang C 2002 Oncogene 21, 2854-2863). Other genes controlled via ERR α comprise the medium chain acetyl dehydrogenase MCAD , Thyroid receptor alpha, osteopontin, PS2 and lactoferrin.

The compounds according to the invention may be used as medicaments, in particular for the manufacture of a medicament for the prevention or treatment of a NR3B1 receptor protein or NR3B1 receptor protein homologue mediated disease or condition in a mammal wherein the prevention or treatment is directly or indirectly accomplished through the binding of the compound according to the invention to the NR3B1 receptor protein or NR3B1 receptor protein homologue. These pharmaceutical compositions contain 0,1 % to 99,5 % of the compound according to the invention, more particularly 0,5 % to 90 % of the compound according to the invention in combination with a pharmaceutically acceptable carrier.

The invention relates also to the use of a compound according to the invention for the manufacture of a medicament for the prevention or treatment of a NR3B1 receptor protein mediated disease or condition wherein the mammal described above is a human. The medicament may be used for regulating the growth of cancer cells in a mammal preferentially a human by modulating the NR3B1 receptor, for regulating cancer, osteoporosis, lipid disorders or a cardiovascular disorder in humans or influencing fertility and reproductive health.

The further concerns the use of a compound according to the invention for the manufacture of a medicament capable for blocking in a mammal, preferentially a human the fatty acid absorption in the intestine. Further the claimed compound may be used for the manufacture of a medicament for treating obesity in humans and for modulating a gene whose expression is regulated by the NR3B1 receptor (see details above and figures). The invention further concerns the use of a compound according to the invention for the manufacture of antitumor medicaments. The antitumor effects of such medicaments could be exerted by selective inhibition of cell proliferation and induction of apoptosis of tumour cells.

The invention shall now be further described in the following examples, without being limited thereto. In the accompanying figure and the sequence protocol,

SEQ ID NO. 1: shows the peptide sequence of ERRa,

SEQ ID NO. 2: shows the nucleotide sequence of the region that encodes for ERRa,

SEQ ID NO. 3: depicts the sequence of the biotinylated SRC1 peptide,

SEQ ID NO. 4: shows primer ERRE_1, used in Examples 3 and 4,

SEQ ID NO. 5: shows primer ERRE_2, used in Examples 3 and 4,

SEQ ID NO 6 is the protein sequence of the ERRb protein,

SEQ ID NO 7 is the mRNA sequence coding for the ERRb protein,

SEQ ID NO 7 is the protein sequence of the ERRg protein, and

SEQ ID NO 8 is the mRNA sequence of the ERRg protein.

Fig. 1 shows the synthesis of the compounds according to the invention as also described in Example 2.

Fig. 2 shows the measurement parameters employed by the Wallace VICTOR2V™ Multilabel Counter which was used for measuring the EC₅₀ values

Figure 3 A shows SEQ ID NO. 1 which is the protein sequence of the ERRa protein a portion of which was used for cloning as described in the examples . Figure 3 B shows SEQ ID NO. 2 which is the mRNA sequence of the ERRa protein. Figure 3 C shows SEQ ID NO. 3 which is the sequence of the biotinylated SRC1 peptide. Figure 3D shows SEQ ID NO 4 which is the protein sequence of the ERRb protein a portion of which was used according to the example described for ERRa. Figure 3E shows SEQ ID NO 5 which is the mRNA sequence coding for the ERRb protein. Figure 3F show SEQ ID NO 6 which is the protein sequence of the ERRg protein, a portion of which was used for cloning according to the example described for ERRa. Figure 3G shows SEQ ID NO 7 which is the mRNA sequence of the ERRg protein.

Fig. 4 shows the internal molecular name used by the applicant (MOLNAME) as well as the corresponding structures of preferred compounds according to the invention. The figure further shows their respective EC₅₀ values (EC50 AVG) as established according to the example 1 in multiple experiments (see above), as well as their respective estimated average efficacy (% activity relative to DES control antagonist).

Figure 5 shows various known ERRa ligands. It is apparent from their structures that the inventors have identified novel compounds which are structurally not related to these known ligands.

Figure 6 shows various genes that have been found to be regulated through binding of an ERRa protein.

Figure 7 shows a dose-dependent transrepression (EC₅₀ ~ 1-5 μ M) of the ERRa reporter gene by ERRa by 01723 (A) or 07831 (B).

Figure 8 shows the stimulation of the ERRa driven reporter gene activity by RIP140 and repression of this RIP140 dependent activity by 10 μ M 01723, 07831 or DES.

Figure 9 shows the ERRa ligand DES and the compound 01723, inhibit growth of the ER negative breast cancer cell line MDA-MB-231 (Fig. 9A). The compound 01723 does not induce proliferation of the ER positive breast cancer cell line T47D, while both E2 (estradiol) and DES stimulate the growth of T47D cells at indicated concentrations (Fig 9B).

EXAMPLES

EXAMPLE 1:

In vitro screening for compounds which influence ERRa binding to coactivators.

For screening purposes a fragment of the open reading frame of human ERR alpha (NR3B1 - (Acc. No: NM_004451)) encoding aminoacids 187-472 was amplified by standard RT PCR procedures (see figures; SEQ ID NO. 1 and 2). Starting material was total RNA derived from human uterus. The resulting cDNA obtained after reverse transcription was subsequently cloned using the GatewayTM recombination technology (Invitrogen, USA) into the expression

plasmid pDest15 (Invitrogen, USA). This construct was used to express a recombinant GST-ERRa fusion protein in E.coli (BL21 strain). For E. coli expression of both constructs, plasmid DNA was transformed into chemically competent E. coli BL21 (Invitrogen, USA) and cells were grown to an OD600 of 0.4-0.7 before expression was induced by addition of 0,5 mM IPTG according instructions of the manufacturer (Invitrogen). After induction for 8 hours at 30°C cells were harvested by centrifugation for 10 minutes at 5000 x g. Fusion proteins were affinity purified using Glutathion sepharose (Pharmacia) or Ni-NTA Agarose (QIAGEN) according to the instructions of the respective manufacturer. Recombinant proteins were dialyzed against 20 mM Tris/HCL pH 7.9; 60 mM KCl; 5 mM MgCl₂; 1 mM DTT, 0,2 mM PMSF; 10% glycerol.

For screening of compound libraries as provided for by the methods shown below in the examples for substances which influence the ERRa/SRC1 interaction, the Perkin Elmer LANCE technology was applied. This method relies on the binding dependent energy transfer from a donor to an acceptor fluorophore attached to the binding partners of interest. For ease of handling and reduction of background from compound fluorescence LANCE technology makes use of generic fluorophore labels and time resolved detection (for detailed description see Hemmilä I, Blomberg K and Hurskainen P, Time-resolved resonance energy transfer (TR-FRET) principle in LANCE, Abstract of Papers Presented at the 3 rd Annual Conference of the Society for Biomolecular Screening, Sep., California (1997)).

For screening, 80 ng of biotinylated SRC1 peptide and 10-200 ng of GST-ERRa fragment were combined with 0.5-2 nM LANCE Eu-(W1024) labelled anti-GST antibody (Perkin Elmer) and 0,5-2µg of Highly fluorescent APC-labelled streptavidin (Perkin Elmer) in the presence of 50µM of individual compounds to be screened in a total volume of 25 µl of 10 mM Hepes pH 7.9; 550 mM NaCl; 2 mM MgCl₂; 40ng/µl BSA. DMSO content of the samples was kept below 1%. Samples were incubated for a minimum of 60 minutes in the dark at room temperature in FIA-Plates black 384well med. binding (Greiner).

The LANCE signal was detected by a Perkin Elmer VICTOR2V™ Multilabel Counter applying the detection parameters listed in Fig. 2. The results were visualized by plotting the ratio between the emitted light at 665 nm and at 615 nm. For every batch of recombinant proteins amount of proteins and labeling reagents giving the most sensitive detection of hits was determined individually by analysis of dose response curves for DES.

EXAMPLE 2:

Experimental procedure for the preparation of the compounds according to the invention (see also Fig 1).

Step 1. General procedure for preparation of Br-Wang resin

1.6 g of Wang resin (1.28 mmol/g, 2.0 mmol/bag) was placed in a porous polypropylene packets (Tea-bag, 60 mm x 50 mm, 65 μ), sealed and transferred to a 125 ml PP bottle. A freshly prepared solution of PPh_3Br_2 (6.1 mmol, 3.0 equivalents, 0.15 M) in DCM (40 mL) was added to each packet. After shaking for 4-6 hours at room temperature, the packet was washed with DCM (5x80 ml) and diethyl ether (4x80 ml). The packet was dried overnight under vacuum to afford off-white resin.

Step 2. Reaction of Acetophenones with Br-Wang resin.

Each packet containing freshly prepared Br-Wang resin was transferred to an appropriate glass bottle, to which an Acetophenone (20 mmol, 10 equivalents, 0.2 M), anhydrous DMA (100 ml) and KOtBu (20 mmol, 10 equivalents, 0.2 M) were added sequentially. After heating at 50°C for 24 hours, the packet was washed alternatively with DMF (3x80 ml) and MeOH (2x80 ml) followed by DCM (2x80 ml) and MeOH (3x80 ml). The packet was air-dried overnight to afford off-white to pale brown resin, depending on the Acetophenone used in the synthesis.

Step 3. Reaction of Aldehydes with Wang resin-bound Acetophenones.

Each packet of Acetophenone-Wang resin was transferred to a 250 mL PP bottle, to which a solution of NaOMe (40 mmol, 20 eq, 0.25 M) in 50%THF-MeOH (160 ml) and an Aldehyde (40 mmol, 20 equivalents, 0.25 M) were added sequentially. After shaking at room temperature for 3 days, the packet was washed several times with MeOH (3x80 ml) and alternatively with DMF (80 ml) and MeOH (80 ml) for 3 cycles, followed by washes of DCM (2x80 ml) and MeOH (3x80 ml). The packet was air-dried overnight to afford a resin-bound chalcone, that varied in color from yellow to dark red depending on the aldehyde used.

Step 4: Reaction of Hydrazines with Wang resin-bound Chalcone.

The tea bag containing the Chalcone on Wang resin from step was cut open and the resin was equally distributed into 40 wells of a microtiter plate (approx. 50 mg, 0.0575 mmol for each

well). The appropriate Hydrazine (0.575 mmol, 10 eq, 0.32 M), NaOH (1.15 mmol, 20 eq, 0.65 M) and MeOEtOH (1.8 mL) were mixed for 2 hrs at room temperature. The supernatant (hydrazine solution) was then added to the corresponding well. The plate was tightly capped, gently shaken and incubated at 75 °C for 24 hours. Each plate was washed alternatively with DMSO (5x 1 mL/well), DMF (6x 1 mL/well), and MeOH (8x 1 mL/well). The plate was air-dried overnight and under vacuum for 4 hours.

Step 5. Air Oxidation of Pyrazoline in acetic acid:

To each well of microtiter plate containing the pyrazoline resins was added 1 ml of acetic acid which was bubbled with air for 20 minutes. The plates were tightly capped , gently shaken , and incubated at 75°C for 48 hours. Each plate was washed alternatively with DMF (6x 1 mL/well) and MeOH (8x 1 mL/well). The plate was air-dried overnight. and under vacuum for 4 hours.

STEP 6. CLEAVAGE FROM LINKER AND EXTRACTION

To dry microtiter plates containing the pyrazole-resins was added 0.5 mL of 20% TFA/DCM to each well. The plates were capped and placed on a shaker at room temperature for 3 h. The plates were transferred to a GENEVAC to remove the volatile TFA/DCM solution. The plates were extracted with AcOH and the extract frozen and lyophilised to afford the title compounds. All of the final products were analysed by HPLC/MS using ELSD detection to determine purity.

EXAMPLE 3:

This example illustrates that a compound according to the invention (experiments shown were done with MOLSTRUCTURE 01723 and 07831(see figure 4 for structural formula) can mediate repression of ERRa mediated transcription in HEK293 cells.

HEK293-were transiently transfected with the pTRexDest30 (Invitrogen) derivatives pTRex-Dest30-hERRa and the pGL2promoter (Promega) derivative pGL2promoter-ERR-RE2. The Renilla-Luciferase pRL-CMV Vector (Promega) was included as a control for transfection efficiency.

The full length human ERRa (accession NM_004451) was cloned into the pTRexDest30 applying the manufacturer protocols for the GatewayTM system (Invitrogen). The

pGL2promoter-ERR-RE2 (ERRa reporter gene construct) was generated by annealing oligonucleotides ERRE_1 (5'-TCGAGGCGATTGTCAAGGTCACACAGTA-3') (SEQ ID No. 4) and ERRE_2 (5'-TCGATACTGTGTGACCTTGACAAATCGCC-3') (SEQ ID No. 5) and cloning them into the Xho I site of the pGL2promoter (Promega). The oligonucleotides contain a consensus ERR response element (underlined). Sequencing confirmed the presence of two copies of the ERR RE.

Luciferase reporter activity was measured in triplicates from extracts of cells after incubating cells in culture medium (phenolred-free DMEM [Gibco-BRL] + 10% charcoal treated FBS [Perbio Science GmbH]) for 16 hours (5% CO₂, 37°C) containing 0,001% DMSO (control) or 0,001% DMSO with increasing concentrations of 01723 or 07831.

A dose-dependent repression (EC₅₀ ~ 1-5 µM) of the reporter gene driven by ERRa was observed for the compounds TR0960001723 (Fig. 7A) and TR0960007831 (Fig. 7 B). Variations of triplicate measurements are indicated.

Example 4:

This example illustrates that a compound according to the invention (experiments shown were done with MOLSTRUCTURE TR0960001723 and TR0960007831 and DES as a control (see figure 4 and 5 for structural formula) can mediate repression of ERRa mediated transcription in HEK293 cells.

HEK293-were transiently transfected with the pTRexDest30 (Invitrogen) derivatives pTRexDest30-hERRa and pTRexDest30-hRIP140 and the pGL2promoter (Promega) derivative pGL2promoter-ERR-RE2. The Renilla-Luciferase pRL-CMV Vector (Promega) was included as a control for transfection efficiency.

The full length human ERRa (accession NM_004451) and RIP140 (X84373) were cloned into the pTRexDest30 applying the manufacturer protocols for the Gateway™ system (Invitrogen).

The pGL2promoter-ERR-RE2 was generated by annealing oligonucleotides ERRE_1 (5'-TCGAGGCGATTGTCAAGGTCACACAGTA-3') (SEQ ID No. 4) and ERRE_2 (5'-TCGATACTGTGTGACCTTGACAAATCGCC- 3') (SEQ ID No. 5) and cloning them into the Xho I site of the pGL2promoter (Promega). The oligonucleotides contain a consensus

ERR response element (underlined). Sequencing confirmed the presence of two copies of the ERR RE.

Luciferase reporter activity was measured in triplicates from extracts of cells after incubating cells in culture medium (phenolred-free DMEM [Gibco-BRL] + 10% charcoal treated FBS [Perbio Science GmbH]) for 16 hours (5% CO₂, 37°C) containing 0,001% DMSO (control) or 0,001% DMSO with increasing concentrations of 01723 or 07831.

The activity of the ERRa reporter gene construct in HEK293 cells is enhanced when ERRa is cotransfected. This activity is further enhanced, when RIP140 is cotransfected in addition. The observed enhancement of ERRa activity is significantly reduced, when 10 µM of either DES or TR0960001723 or TR0960007831 are added to the medium (see Fig 8)

EXAMPLE 5:

This example illustrates that a compound according to the patent (MOLSTRUCTURE TR0960001723; see figure 4 for structural formula) can inhibit proliferation of an estrogen receptor negative cell line (MDA-MB-231).


Cell proliferation assays were performed with MDA-MB-231 cells (ER negative) and T47D cells (ER positive) in the presence of 17β-estradiol (E2), DES, TR0960001723 or TR0960007831. Cells were seeded in 96-well plates at a density of 15,000 (MDA-MB-231) or 10,000 (T47D) cells/100 µl/well in phenol red-free DMEM (Gibco-BRL) containing 10% (MDA-MB-231) or 2% (T47D) charcoal dextran treated FBS (Perbio Science GmbH). Treatment media containing either 0,1% DMSO (control) or 0,1% DMSO with increasing concentrations of compounds (as indicated) were added on the following day and replaced at 72h-intervals until the end of the experiment. At 6 days (MDA-MB-231) or 8 days (T47D) after initiation of the treatment a colorimetric proliferation assay was performed using CellTiter 96 Aqueous nonradioactive proliferation assay as directed by the manufacturer (Promega). Cell proliferation rates were measured as absorbance of the formazan product at 490 nm. Values are expressed as percentage of control (DMSO) and represent the means of three replicates.

As observed, DES and 17β-estradiol stimulated T47D cell proliferation at 1 nM to 100 nM, but TR0960001723 had no effect (Fig.9B). In contrast, DES and TR0960001723 inhibited proliferation of MDA-MB-231 cells whereas 17β-estradiol did not (Fig 9A).

Claims:

1. A compound according to formula (1), or pharmaceutical acceptable salts or solvates thereof,

formula (1)



wherein:

R₁ is phenyl, substituted phenyl, C₅ to C₆ heteroaryl, C₅ to C₆ substituted heteroaryl, naphthyl or substituted naphthyl,

R₂ is H, C₁ to C₈ alkyl, C₁ to C₇ acyl or C₁ to C₇ substituted acyl, C₁ to C₈ substituted alkyl, C₇ to C₁₂ alkylphenyl or C₇ to C₁₂ substituted phenylalkyl, C₃ to C₈ cycloalkyl, C₃ to C₈ substituted cycloalkyl, C₅ to C₆ heteroaryl, [C₅ to C₆]-heteroaryl-(C₁ to C₆)-alkyl, and

R₃ is H, C₁ to C₈ alkyl, C₁ to C₈ substituted alkyl, C₇ to C₁₂ alkylphenyl or C₇ to C₁₂ substituted phenylalkyl, halogen, C₁ to C₈ alkoxy, furanyl, substituted furanyl, thiazyl, substituted thiazyl, carboxy, ester, amide or C₁ to C₈ aminoacyl.

2. A compound according to claim 1, or pharmaceutical acceptable salts or solvates thereof, wherein:


R₁ is phenyl, or substituted phenyl, C₅ to C₆ heteroaryl, C₅ to C₆ substituted heteroaryl,

R₂ is H, CH₃, substituted alkyl or substituted phenyl, and

R₃ is substituted phenyl, C₅ to C₆ heteroaryl or C₅ to C₆ substituted heteroaryl.

3. A compound according to claim 2, or pharmaceutical acceptable salts or solvates thereof, wherein:
R₁ is substituted phenyl,
R₂ is CH₃ or substituted alkyl, and
R₃ is substituted phenyl or substituted C₅ heteroaryl.
4. A compound according to claim 1, having the following formula (2)

formula (2)




wherein:

- R₂ is H, C₁ to C₈ alkyl, C₁ to C₈ substituted alkyl, C₇ to C₁₂ alkylphenyl or C₇ to C₁₂ substituted phenylalkyl,
R₄ is H, C₁ to C₈ alkyl, halogen, C₁ to C₈ alkoxy, carboxy, ester, amide or C₁ to C₈ aminoacyl, and
R₅ is H, C₁ to C₈ alkyl, halogen, C₁ to C₈ alkoxy, carboxy, ester, amide or C₁ to C₈ aminoacyl.

5. A compound according to any of claims 1 to 4 having the following formula (3)

formula (3)




wherein:

R₂ is H, C₁ to C₇ acyl or C₁ to C₇ substituted acyl, phenyl, substituted phenyl, C₅ to C₆ heteroaryl, C₅ to C₆ substituted heteroaryl, naphthyl or substituted naphthyl,

R₆ is H, C₁ to C₈ alkyl, C₁ to C₈ substituted alkyl, C₇ to C₁₂ alkylphenyl or C₇ to C₁₂ substituted phenylalkyl, carboxy, ester, amide or C₁ to C₈ aminoacyl, C₁ to C₈ alkoxy.

6. A compound according to any of claims 1 to 4 having the following formula (4)

formula (4)



wherein:

R₂ is H, C₁ to C₇ acyl or C₁ to C₇ substituted acyl, phenyl, substituted phenyl, C₅ to C₆ heteroaryl, C₅ to C₆ substituted heteroaryl, naphthyl or substituted naphthyl,

R₆ is H, C₁ to C₈ alkyl, C₁ to C₈ substituted alkyl, C₇ to C₁₂ alkylphenyl or C₇ to C₁₂ substituted phenylalkyl, carboxy, ester, amide or C₁ to C₈ aminoacyl, C₁ to C₈ alkoxy.

7. A compound according to any of claims 1 to 6 wherein said compound is capable of binding the NR3B1 receptor protein or a portion thereof according to SEQ ID NO. 3 or a mammalian homologue thereof.
8. A compound according to any of claims 1 to 6 wherein said compound is capable of modulating the activity of the NR3B1 receptor protein comprising antagonistic or agonistic effects.

9. A method for prevention or treatment of a NR3B1 receptor protein or NR3B1 receptor protein homologue mediated disease or condition in a mammal comprising administration of a therapeutically effective amount of a compound according to any of claims 1 to 6 wherein the prevention or treatment is directly or indirectly accomplished through the binding of the compound according to any of claims 1 to 8 to the NR3B1 receptor protein or to the NR3B1 receptor protein homologue.
10. A method for prevention or treatment of a NR3B1 receptor protein mediated disease or condition according to claim 9 wherein the mammal is a human.
11. A method for regulating physiologies that are influenced by estrogenic response pathways in a mammal comprising modulating the activity of the NR3B1 receptor with a therapeutically effective amount of a compound according to any of claims 1 to 8.
12. A method of treating in mammal a disease which is directly or indirectly affected by estrogen levels comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to any of claims 1 to 8.
13. A method of treating cancer, osteoporosis, obesity, lipid disorders or a cardiovascular disorder or influencing fertility and reproductive health in a mammal, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound according to any of claims 1 to 8.
14. A method of modulating the expression of a gene directly or indirectly controlled by NR3B1 in tissues of a mammal comprising administering to a mammal in need of such modulation an effective amount of a compound according to any of claims 1 to 8.
15. The method of claim 13 or 14, wherein said mammal is a human.
16. Use of a method according to claim 15 for treating cancer, osteoporosis, lipid disorders or a cardiovascular disorder in humans or influencing fertility and reproductive health.
17. A method according to claim 14 wherein the expression of genes comprising aromatase, MCAD, thyroid receptor alpha, osteopontin, PS2, lactoferrin is modulated.

18. Use of a compound according to any of the claims 1 to 8 as a medicament.
19. Use of a compound according to any of claims 1 to 8 for the manufacture of a medicament for the prevention or treatment of a NR3B1 receptor protein or NR3B1 receptor protein homologue mediated disease or condition in a mammal wherein the prevention or treatment is directly or indirectly accomplished through the binding of the compound according claims 1 to 8 to the NR3B1 receptor protein or NR3B1 receptor protein homologue.
20. Use of a compound according to any of claims 1 to 8 for the manufacture of a medicament for prevention or treatment of a NR3B1 receptor protein mediated disease or condition according to claim 19 wherein the mammal is a human.
21. Use of a compound according to any of claims 1 to 8 for the manufacture of a medicament for regulating estrogenic signaling systems in a mammal by modulating the NR3B1 receptor.
22. Use of a compound according to any of claims 1 to 8 for the manufacture of a medicament for regulating levels of aromatase, bone morphogenic, and/or lipogenic factors or proteins.
23. Use of a compound according to any of claims 1 to 8 for the manufacture of a medicament for treating in a mammal cancer, osteoporosis, obesity, atherosclerosis, lipid disorders or a cardiovascular disorder or influencing fertility and reproductive health.
24. Use of a compound according to any of claims 1 to 8 for the manufacture of a medicament capable for blocking in a mammal the proliferation of estrogen receptor positive and estrogen receptor negative cells, in particular cancer cells.
25. Use of the compound according to claim 24 for the manufacture of a medicament for treating obesity in a mammal, in particular a human.

26. Use of a compound according to any of claims 1 to 8 for the manufacture of a medicament for modulating a gene whose expression is regulated by the NR3B1 receptor.

FB11719
LION bioscience AG

ABSTRACT

The present invention relates to compounds according to the general formula (1) which bind to the NR3B1 receptor and act as antagonists or agonists of the NR3B1 receptor. The invention further relates to the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and the production of medicaments using said compounds.

Fig. 1




Fig. 2 : Measurement parameters employed by the Wallace VICTOR2V™ Multilabel Counter:

Number of repeats	1
plate: GREINER FIA-Plate black 384 well med. binding	
Measurement height	3.50 mm
Label technology	TR-F Lance
Emission filter name	D615
Emission filter slot	A1
Emission aperture	Normal
Excitation filter	D340
Delay	50 μ s
Window time	400 μ s
Cycle	1000 μ s
Light integrator capacitors	1
Light integrator ref. level	95
Flash energy area	High
Flash energy level	223
Flash absorbance measurement	No
Beam	Normal
Label technology	TR-F Lance
Emission filter name	D665
Emission filter slot	A8
Emission aperture	Normal
Excitation filter	D340
Delay	50 μ s
Window time	400 μ s
Cycle	1000 μ s
Light integrator capacitors	1
Light integrator ref. level	95
Flash energy area	High
Flash energy level	223
Flash absorbance measurement	No
Beam	Normal

Fig. 3 A, B, C, D, E , F and G**A**

```

1  MGLEMSSKDS  PGSLDGRAWE  DAQKPQSAWC  GGRKTRVYAT  SSRRAPPSEG  TRRGGAARPE
61  EAAEEGPPAA  PGSLRHSGPL  GPHACPTALP  EPQVTSAMSS  QVVGIEPLYI  KAEPASPDSP
121 KGSSETETEP  PVALAPGPAP  TRCLPGHKEE  EDGEGAGPGE  QGGGKLVLS  LPKRLCLVCG
181 DVASGYHYGV  ASCEACKAFF  KRTIQGSIEY  SCPASNECEI  TKRRRKACQA  CRFTKCLRVG
241 MLKEGVRLDR  VRGGRQKYKR  RPEVDPLPFP  GPFPAGPLAV  AGGPRKTAPV  NALVSHLLVV
301 EPEKLYAMPD  PAGPDGHLPA  VATLCDLFDR  EIVVTISWAK  SIPGFSSLSL  SDQMSVLQSV
361 WMEVLVLGVA  QRSPLQLDEL  AFAEDLVLDE  EGARAAGLGE  LGAALLQLVR  RLQALRLERE
421 EYVLLKALAL  ANSDSVHIED  AEAVEQLREA  LHEALLEYEA  GRAGPGGGAE  RRRAGRLLLT
481 LPLLRTAGK  VLAHFYGVKL  EGKVPMHKLF  LEMLEAMMD

```

B

```

1  atgggattgg  agatgagctc  caaggacagc  cctggcagtc  tggatggaag  agcttgggaa
61  gatgctcaga  aaccacaaag  tgcctggtgc  ggtgggagga  aaaccagagt  gtatgctaca
121 agcagccggc  gggcgccgcc  gagtgagggg  acgcggcgcg  gtggggcggc  gcgggccgag
181 gaggcggcgg  aggagggggc  gcccgcggcc  cccggctcac  tccggcactc  cgggcccgtc
241 ggcccccatg  cctgcccagc  cgcgctgccc  gagccccagg  tgaccagcgc  catgtccagc
301 cagggtggtg  gcattgagcc  tctctacatc  aaggcagagc  cggccagccc  tgacagtcca
361 aagggttcct  cggagacaga  gaccgagcct  cctgtggccc  tggcccctgg  tccagctccc
421 actcgctgcc  tcccaggcca  caaggaagag  gaggatgggg  agggggctgg  gcctggcgag
481 cagggcggtg  ggaagctggt  gctcagctcc  ctgcccagc  gcctctgcct  ggtctgtggg
541 gacgtggcct  ccggctacca  ctatggtgtg  gcatcctgtg  aggcctgcaa  agccttcttc
601 aagaggacca  tccaggggag  catcgagtac  agctgtccgg  cctccaacga  gtgtgagatc
661 accaagcgga  gacgcaaggc  ctgccaggcc  tgccgcttca  ccaagtgcct  gcggtggggc
721 atgctcaagg  agggagtgcg  cctggaccgc  gtccgggggt  ggcggcagaa  gtacaagcgg
781 cgcccgagg  tggaccact  gcccttccc  ggcccttcc  ctgctgggccc  cctggcagtc
841 gctggaggcc  ccggaagac  agcagcccca  gtgaatgcac  tgggtgtctca  tctgctggtg
901 gttgagcctg  agaagctcta  tgccatgcct  gaccccgag  gccctgatgg  gcacctccca
961 gccgtggcta  ccctctgtga  cctctttgac  cgagagattg  tggtcaccat  cagctggggc
1021 aagagcatcc  caggcttctc  atcgctgtcg  ctgtctgacc  agatgtcagt  actgcagagc
1081 gtgtggatgg  aggtgctggt  gctgggtgtg  gccagcgct  cactgccact  gcaggatgag
1141 ctggccttcg  ctgaggactt  agtctggat  gaagaggggg  cacgggcagc  tggcctgggg
1201 gaactggggg  ctgccctgct  gcaactagt  cgcggtgc  aggcctgcg  gctggagcga
1261 gaggagtatg  ttctactaaa  ggccttgccc  cttgccaatt  cagactctgt  gcacatcgaa
1321 gatgagccga  ggctgtggag  cagctgcgag  aagctcctgc  acgaggccct  gctggagtat
1381 gaagccggcc  gggctggccc  cggaggggg  gctgagcggc  ggcggggcgg  caggctgctg
1441 ctacagctac  cgctcctccg  ccagacagcg  ggcaaagtgc  tggcccattt  ctatgggggtg
1501 aagctggagg  gcaaggtgcc  catgcacaag  ctgttcttgg  agatgctcga  ggccatgatg

```

1561 gactga

C

Biotin-CPSSHSSLTERHKILHRLLEQEGSPS-COOH

D

1 MSSDDRHLGS SCGSFIKTEP SSPSSGIDAL SHHSPSGSSD ASGGFGLALG THANGLDSPP
 61 MFAGAGLGGT PCRKSYEDCA SGIMEDSAIK CEYMLNAIPK RLCLVCGDIA SGYHYGVASC
 121 EACKAFFKRT IQGNIEYSCP ATNECEITKR RRKSCQACRF MKCLKVGMLK EGVRLDRVRG
 181 GRQKYKRRLD SESSPYLSLQ ISPPAKKPLT KIVSYLLVAE PDKLYAMPPP GMPEGDIKAL
 241 TTLCDLADRE LVVIIGWAKH IPGFSSLSLG DQMSLLQSAW MEILILGIVY RSLPYDDKLV
 301 YAEDYIMDEE HSRLAGLLEL YRAILQLVRR YKKLKVEKEE FVTLKALALA NSDSMYIEDL
 361 EAVQKLQDLL HEALQDYELS QRHEEPWRTG KLLLTLPPLR QTAAKAVQHF YSVKLQGVKVP
 421 MHKLFLEMLE AKAWARADSL QEWRPLEQVP SPLHRATKRQ HVHFLTPLPP PPSVAWVGTA
 481 QAGYHLEVFL PQRAGWPRAA

E

1 atgtcctcgg acgacaggca cctgggctcc agctgcggct ccttcacaa gactgagccg
 61 tccagcccgt cctcgggcat agatgcctc agccaccaca gcccagtggt ctcgtccgac
 121 gccagcggcg gctttggcct ggccctgggc acccacgcca acggtctgga ctcgccaccc
 181 atgtttgcag gcgcccgggt gggaggcacc ccatgccgca agagctacga ggactgtgcc
 241 agcggcatca tggaggactc ggccatcaag tgcgagtaca tgctcaacgc catccccaag
 301 cgcctgtgcc tcgtgtgcgg ggacattgcc tctggctacc actacggcgt ggcctcctgc
 361 gaggcttgca aggccttctt caagaggact atccaaggga acattgagta cagctgcccg
 421 gccaccaacg agtgcgagat caccaaaccg aggcgcaagt cctgccaggc ctgccgcttc
 481 atgaaatgcc tcaaagtggg gatgctgaag gaaggtgtgc gccttgatcg agtgcggtga
 541 ggccgtcaga aatacaacg acggctggac tcagagagca gccatacct gagcttaciaa
 601 atttctccac ctgctaaaaa gccattgacc aagattgtct catacctact ggtggctgag
 661 ccggacaagc tctatgccat gcctccccct ggtatgcctg agggggacat caaggccctg
 721 accactctct gtgacctggc agaccgagag cttgtggtca tcattggctg ggccaagcac
 781 atcccaggct tctcaagcct ctccctgggg gaccagatga gcctgctgca gagtgcctgg
 841 atggaaatcc tcatcctggg catcgtgtac cgctcgctgc cctacgacga caagctgggtg
 901 tacgctgagg actacatcat ggatgaggag cactcccgc tcgcggggct gctggagctc
 961 taccgggcca tcctgcagct ggtacgcagg tacaagaagc tcaaggtgga gaaggaggag
 1021 tttgtgacgc tcaaggccct ggccctcgcc aactccgatt ccatgtacat cgaggatcta
 1081 gaggctgtcc agaagctgca ggacctgctg caccaggcac tgcaggacta cgagctgagc
 1141 cagcgccatg aggagccctg gaggacgggc aagctgctgc tgacactgcc gctgctgcgg
 1201 cagacggccg ccaaggccgt gcagcacttc tatagcgtca aactgcaggg caaagtgccc
 1261 atgcacaaac tcttcctgga gatgctggag gccaaaggcct gggccagggc tgactccctt

1321 caggagtgga ggccactgga gcaagtgcc tctccctcc accgagccac caagaggcag
 1381 catgtgcatt tcctaactcc cttgccccct ccccatctg tggcctgggt gggcactgct
 1441 caggctggat accacctgga ggttttcctt ccgcagaggg caggttggcc aagagcagct
 1501 tag

F

1 MSNKDRHIDS SCSSFIKTEP SSPASLTDSV NHSPGGSSD ASGSYSSTMN GHQNGLDSP
 61 LYPAPILGG SGPVRKLYDD CSSTIVEDPQ TKCEYMLNSM PKRLCLVCGD IASGYHYGVA
 121 SCEACKASFK RKIQANIEYS CPATNECEIT KRRRKSCQAC RFMKCLKVGM LKEGVRLDRV
 181 RGGKQKYKRR IDAENSPYLN PQLVQPAKKP YNKIVSHLLV AEPEKIYAMP DPTVPDSDIK
 241 ALTTLCDCAD RELVVIIGWA KHIPGFSTLS LADQMSLLQS AWMEILILGF VYRSLSFED
 301 LUYADDYIMD EDQSKLAGLL DLNNAILQLV KKYKSMKLEK EEFVTLKAIA LANSDSMHIE
 361 DVEAVQKLQD VLHEALQDYE AGQHMEDPRR AGKMLMTLPL LRQTSTKAVQ HFYNIKLEK
 421 VPMHKL FLEM LEAKVC


G

1 atggattcgg tagaactttg ccttcctgaa tctttttccc tgcactacga ggaagagctt
 61 ctctgcagaa tgtcaaaca agatcgacac attgattcca gctgttcgtc cttcatcaag
 121 acggaacctt ccagcccagc ctccctgacg gacagcgtca accaccacag ccctgggtggc
 181 tcttcagacg ccagtgggag ctacagttca accatgaatg gccatcagaa cggacttgac
 241 tcgccacctc tctacccttc tgctcctatc ctgggaggta gtgggcctgt caggaaactg
 301 tatgatgact gctccagcac cattgttgaa gatccccaga ccaagtgtga atacatgctc
 361 aactcgatgc ccaagagact gtgttttagt tggtgtgaca tcgcttctgg gtaccactat
 421 ggggtagcat catgtgaagc ctgcaaggca ttcttcaaga ggacaattca aggcaatata
 481 gaatacagct gccctgccac gaatgaatgt gaaatcacia agcgcagacg taaatcctgc
 541 caggcttgcc gcttcatgaa gtgtttaaaa gtgggcatgc tgaaagaagg ggtgcgtctt
 601 gacagagtac gtggagggtc gcagaagtac aagcgcagga tagatgcgga gaacagccca
 661 tacctgaacc ctgagctggg tcagccagcc aaaaagccat ataacaagat tgtctcacat
 721 ttgttggtgg ctgaaccgga gaagatctat gccatgcctg accctactgt ccccgacagt
 781 gacatcaaag cctcactac actgtgtgac ttggccgacc gagagttggg gggttatcatt
 841 ggatgggca agcatattcc aggttctcc acgctgtccc tggcggaaca gatgagcctt
 901 ctgcagagtg cttggatgga aattttgatc cttggtgtcg tataccgggtc tctttcattt
 961 gaggatgaac ttgtctatgc agacgattat ataatggacg aagaccagtc caaattagca
 1021 ggccttcttg atctaaataa tgctatcctg cagctggtaa agaaatacaa gagcatgaag
 1081 ctggaaaaag aagaatttgt caccctcaa gctatagctc ttgctaattc agactccatg
 1141 cacatagaag atgttgaagc cgttcagaag cttcaggatg tcttacatga agcgtgcag
 1201 gattatgaag ctggccagca catggaagac cctcgtcgag ctggcaagat gctgatgaca
 1261 ctgccactcc tgaggcagac ctctaccaag gccgtgcagc atttctacia catcaaacta

1321 gaaggcaaag tcccaatgca caaacttttt ttggaaatgt tggaggccaa ggtctga


Fig 4 Molecule structure EC₅₀ average

DES




7,8

TR0960001723




35,7

TR0960007822




10,1

TR0960007828



12,4

TR0960007831



42,3





Fig. 5:**hexoestrol****DES****resveratrol****dienestrol**

Fig. 6:**Genes regulated by ERR's:**

Lactoferrin (NM_002343)

MCAD (medium chain acylcoenzyme A dehydrogenase) (AH002873)

Thyroid receptor alpha (M24899)

Osteopontin (BC022844)

Aromatase (X13589)

PS2 (XM_009779)

SHP (AB058644)

Fig. 7A




Fig. 7B.




Fig 8




Fig 9A





Fig 9B



SEQUENCE LISTING

<110> LION bioscience

<120> NR3B1 nuclear receptor binding compounds

<130> FB11719

<160> 9

<170> PatentIn version 3.1

<210> 1

<211> 1377

<212> DNA

<213> Homo sapiens

<400> 1

atggattcgg tagaactttg ccttcctgaa tctttttccc tgcactacga ggaagagctt	60
ctctgcagaa tgtcaaacia agatcgacac attgattcca gctgttcgtc cttcatcaag	120
acggaacctt ccagcccagc ctccctgacg gacagcgtca accaccacag ccctgggtggc	180
tcttcagacg ccagtgggag ctacagttca accatgaatg gccatcagaa cggacttgac	240
tcgccacctc tctaccttc tgctcctatc ctgggaggta gtgggcctgt caggaaactg	300
tatgatgact gctccagcac cattgttgaa gatccccaga ccaagtgtga atacatgctc	360
aactcgatgc ccaagagact gtgttttagtg tgtggtgaca tcgcttctgg gtaccactat	420
ggggtagcat catgtgaagc ctgcaaggca ttcttcaaga ggacaattca aggcaatata	480
gaatacagct gccctgccac gaatgaatgt gaaatcacia agcgcagacg taaatcctgc	540
caggcttgcc gcttcatgaa gtgttttaaaa gtgggcatgc tgaaagaagg ggtgcgtctt	600
gacagagtac gtggagggtcg gcagaagtac aagcgcagga tagatgcgga gaacagccca	660
tacctgaacc ctgagctggt tcagccagcc aaaaagccat ataacaagat tgtctcacat	720
ttgttggtgg ctgaaccgga gaagatctat gccatgcctg accctactgt ccccgacagt	780
gacatcaaag ccctcactac actgtgtgac ttggccgacc gagagtgggt gggtatcatt	840
ggatgggcga agcatattcc aggcttctcc acgctgtccc tggcggacca gatgagcctt	900
ctgcagagtg cttggatgga aattttgatc cttggtgtcg tataccggtc tctttcattt	960
gaggatgaac ttgtctatgc agacgattat ataatggacg aagaccagtc caaattagca	1020
ggccttcttg atctaaataa tgctatcctg cagctggtaa agaaatacaa gagcatgaag	1080
ctggaaaaag aagaatttgt caccctcaaa gctatagctc ttgctaattc agactccatg	1140
cacatagaag atgttgaagc cgttcagaag cttcaggatg tcttacatga agcgctgcag	1200
gattatgaag ctggccagca catggaagac cctcgctcgag ctggcaagat gctgatgaca	1260
ctgccactcc tgaggcagac ctctaccaag gccgtgcagc atttctacia catcaaacta	1320
gaaggcaaaag tcccaatgca caaacttttt ttggaaatgt tggaggccaa ggtctga	1377

<210> 2
<211> 1566
<212> DNA
<213> Homo sapiens

<400> 2
atgggattgg agatgagctc caaggacagc cctggcagtc tggatggaag agcttgggaa 60
gatgctcaga aaccacaaag tgcctggtgc ggtgggagga aaaccagagt gtatgctaca 120
agcagccggc gggcgccgcc gagtgagggg acgcggcgcg gtggggcggc gcggcccgag 180
gaggcgggcg aggagggggc gcccgcggcc cccggctcac tccggcactc cgggccgctc 240
ggccccatg cctgcccagc cgcgctgccg gagccccagg tgaccagcgc catgtccagc 300
cagggtggtg gcattgagcc tctctacatc aaggcagagc cggccagccc tgacagtcca 360
aagggttcct cgagacaga gaccgagcct cctgtggccc tggcccctgg tccagctccc 420
actcgtgcc tcccaggcca caaggaagag gaggatgggg agggggctgg gcctggcgag 480
cagggcggtg ggaagctggt gctcagctcc ctgcccaagc gcctctgcct ggtctgtggg 540
gacgtggcct ccggctacca ctatggtgtg gcctcctgtg aggcctgcaa agccttcttc 600
aagaggacca tccaggggag catcgagtac agctgtccgg cctccaacga gtgtgagatc 660
accaagcgga gacgcaaggc ctgccaggcc tgccgcttca ccaagtgcct gcgggtgggc 720
atgctcaagg agggagtgcg cctggaccgc gtccgggggtg ggccggcagaa gtacaagcgg 780
cggccggagg tggaccact gcccttcccg ggccccttcc ctgctgggcc cctggcagtc 840
gctggaggcc cccggaagac agcagcccca gtgaatgcac tgggtgtctca tctgctggtg 900
gttgagcctg agaagctcta tgccatgcct gaccccgag gccctgatgg gcacctccca 960
gccgtggcta ccctctgtga cctctttgac cgagagattg tggtcacat cagctgggcc 1020
aagagcatcc caggcttctc atcgtgtgcg ctgtctgacc agatgtcagt actgcagagc 1080
gtgtggatgg aggtgctggt gctgggtgtg gccagcgct cactgccact gcaggatgag 1140
ctggccttcg ctgaggactt agtcctggat gaagaggggg cacgggcagc tggcctgggg 1200
gaactggggg ctgccctgct gcaactagtg cggcggtgc aggcctgcg gctggagcga 1260
gaggagtatg ttctactaaa ggccttggcc cttgccaaatt cagactctgt gcacatcgaa 1320
gatgagccga ggctgtggag cagctgcgag aagctcctgc acgaggccct gctggagtat 1380
gaagccggcc gggctggccc cggagggggg gctgagcggc ggccggcggg caggctgctg 1440
ctcacgctac cgtcctccg ccagacagcg ggcaaagtgc tggcccattt ctatggggtg 1500
aagctggagg gcaaggtgcc catgcacaag ctgttcttgg agatgctcga ggccatgatg 1560
gactga 1566

<210> 3
<211> 25
<212> PRT
<213> Homo sapiens

<400> 3

Cys Pro Ser Ser His Ser Ser Leu Thr Glu Arg His Lys Ile Leu His
1 5 10 15

Arg Leu Leu Gln Glu Gly Ser Pro Ser
20 25

<210> 4
<211> 29
<212> DNA
<213> Homo sapiens

<400> 4

tcgaggcgat ttgtcaaggt cacacagta

29

<210> 5
<211> 29
<212> DNA
<213> Homo sapiens

<400> 5

tcgatactgt gtgaccttga caaatcgcc

29

<210> 6
<211> 500
<212> PRT
<213> Homo sapiens

<400> 6

Met Ser Ser Asp Asp Arg His Leu Gly Ser Ser Cys Gly Ser Phe Ile
1 5 10 15

Lys Thr Glu Pro Ser Ser Pro Ser Ser Gly Ile Asp Ala Leu Ser His
20 25 30

His Ser Pro Ser Gly Ser Ser Asp Ala Ser Gly Gly Phe Gly Leu Ala
35 40 45

Leu Gly Thr His Ala Asn Gly Leu Asp Ser Pro Pro Met Phe Ala Gly
50 55 60

Ala Gly Leu Gly Gly Thr Pro Cys Arg Lys Ser Tyr Glu Asp Cys Ala
65 70 75 80

Ser Gly Ile Met Glu Asp Ser Ala Ile Lys Cys Glu Tyr Met Leu Asn
85 90 95

Ala Ile Pro Lys Arg Leu Cys Leu Val Cys Gly Asp Ile Ala Ser Gly
100 105 110

Tyr His Tyr Gly Val Ala Ser Cys Glu Ala Cys Lys Ala Phe Phe Lys
115 120 125

Arg Thr Ile Gln Gly Asn Ile Glu Tyr Ser Cys Pro Ala Thr Asn Glu
130 135 140

Cys Glu Ile Thr Lys Arg Arg Arg Lys Ser Cys Gln Ala Cys Arg Phe
145 150 155 160

Met Lys Cys Leu Lys Val Gly Met Leu Lys Glu Gly Val Arg Leu Asp
165 170 175

Arg Val Arg Gly Gly Arg Gln Lys Tyr Lys Arg Arg Leu Asp Ser Glu
180 185 190

Ser Ser Pro Tyr Leu Ser Leu Gln Ile Ser Pro Pro Ala Lys Lys Pro
195 200 205

Leu Thr Lys Ile Val Ser Tyr Leu Leu Val Ala Glu Pro Asp Lys Leu
210 215 220

Tyr Ala Met Pro Pro Pro Gly Met Pro Glu Gly Asp Ile Lys Ala Leu
225 230 235 240

Thr Thr Leu Cys Asp Leu Ala Asp Arg Glu Leu Val Val Ile Ile Gly
245 250 255

Trp Ala Lys His Ile Pro Gly Phe Ser Ser Leu Ser Leu Gly Asp Gln
260 265 270

Met Ser Leu Leu Gln Ser Ala Trp Met Glu Ile Leu Ile Leu Gly Ile
275 280 285

Val Tyr Arg Ser Leu Pro Tyr Asp Asp Lys Leu Val Tyr Ala Glu Asp
290 295 300

Tyr Ile Met Asp Glu Glu His Ser Arg Leu Ala Gly Leu Leu Glu Leu
305 310 315 320

Tyr Arg Ala Ile Leu Gln Leu Val Arg Arg Tyr Lys Lys Leu Lys Val
325 330 335

Glu Lys Glu Glu Phe Val Thr Leu Lys Ala Leu Ala Leu Ala Asn Ser
340 345 350

Asp Ser Met Tyr Ile Glu Asp Leu Glu Ala Val Gln Lys Leu Gln Asp
355 360 365

Leu Leu His Glu Ala Leu Gln Asp Tyr Glu Leu Ser Gln Arg His Glu
370 375 380

Glu Pro Trp Arg Thr Gly Lys Leu Leu Leu Thr Leu Pro Leu Leu Arg
385 390 395 400

Gln Thr Ala Ala Lys Ala Val Gln His Phe Tyr Ser Val Lys Leu Gln
405 410 415

Gly Lys Val Pro Met His Lys Leu Phe Leu Glu Met Leu Glu Ala Lys
420 425 430

Ala Trp Ala Arg Ala Asp Ser Leu Gln Glu Trp Arg Pro Leu Glu Gln
435 440 445

Val Pro Ser Pro Leu His Arg Ala Thr Lys Arg Gln His Val His Phe
450 455 460

Leu Thr Pro Leu Pro Pro Pro Pro Ser Val Ala Trp Val Gly Thr Ala
465 470 475 480

Gln Ala Gly Tyr His Leu Glu Val Phe Leu Pro Gln Arg Ala Gly Trp
485 490 495

Pro Arg Ala Ala
500

<210> 7
<211> 1503
<212> DNA
<213> Homo sapiens

<400> 7
atgtcctcgg acgacaggca cctgggctcc agctgcggct ccttcatcaa gactgagccg 60
tccagcccgt cctcgggcat agatgccctc agccaccaca gcccagtggt ctggtccgac 120
gccagcggcg gctttggcct ggccctgggc acccaccgca acggtctgga ctgccaccc 180
atgtttgcag gcgccgggct gggaggcacc ccatgccgca agagctacga ggactgtgcc 240
agcggcatca tggaggactc ggccatcaag tgcgagtaca tgctcaacgc catccccaaag 300
cgctgtgcc tcgtgiycgg ggacattgcc tctggctacc actacggcgt ggcctcctgc 360
gaggcttgca aggccttctt caagaggact atccaaggga acattgagta cagctgcccg 420
gccaccaacg agtgcgagat caccaaacgg aggcgcaagt cctgccaggc ctgccgttc 480

atgaaatgcc tcaaagtggg gatgctgaag gaaggtgtgc gccttgatcg agtgcgtgga 540
ggccgtcaga aatacaagcg acggctggac tcagagagca gccatacct gagcttacia 600
atttctccac ctgctaaaaa gccattgacc aagattgtct catacctact ggtggctgag 660
ccggacaagc tctatgecat gcctccccct ggtatgcctg agggggacat caaggccctg 720
accactctct gtgacctggc agaccgagag cttgtgtgtca tcattggctg ggccaagcac 780
atcccaggct tctcaagcct ctccctgggg gaccagatga gcctgctgca gagtgcctgg 840
atggaaatcc tcctcctggg catcgtgtac cgctcgtgc cctacgacga caagctggtg 900
tacgctgagg actacatcat ggatgaggag cactcccgcc tcgcggggct gctggagctc 960
taccggggcca tcctgcagct ggtacgcagg tacaagaagc tcaaggtgga gaaggaggag 1020
tttgtgacgc tcaaggccct ggccctcgcc aactccgatt ccatgtacat cgaggatcta 1080
gaggctgtcc agaagctgca ggacctgctg cagcaggcac tgcaggacta cgagctgagc 1140
cagcgccatg aggagccctg gaggacgggc aagctgctgc tgacactgcc gctgctgcgg 1200
cagacggccg ccaaggccgt gcagcacttc tatagcgtca aactgcaggg caaagtgcc 1260
atgcacaaac tcttctctga gatgctggag gccaaaggct gggccagggc tgactccctt 1320
caggagtgga ggccactgga gcaagtgcc tctccctcc accagagccac caagaggcag 1380
catgtgcatt tcctaactcc cttgccccct ccccatctg tggcctgggt gggcactgct 1440
caggctggat accacctgga ggttttcctt ccgcagaggg caggttggcc aagagcagct 1500
tag 1503

<210> 8
<211> 436
<212> PRT
<213> Homo sapiens

<400> 8

Met Ser Asn Lys Asp Arg His Ile Asp Ser Ser Cys Ser Ser Phe Ile
1 5 10 15

Lys Thr Glu Pro Ser Ser Pro Ala Ser Leu Thr Asp Ser Val Asn His
20 25 30

His Ser Pro Gly Gly Ser Ser Asp Ala Ser Gly Ser Tyr Ser Ser Thr
35 40 45

Met Asn Gly His Gln Asn Gly Leu Asp Ser Pro Pro Leu Tyr Pro Ser
50 55 60

Ala Pro Ile Leu Gly Gly Ser Gly Pro Val Arg Lys Leu Tyr Asp Asp
65 70 75 80

Cys Ser Ser Thr Ile Val Glu Asp Pro Gln Thr Lys Cys Glu Tyr Met
85 90 95

Leu Asn Ser Met Pro Lys Arg Leu Cys Leu Val Cys Gly Asp Ile Ala
100 105 110

Ser Gly Tyr His Tyr Gly Val Ala Ser Cys Glu Ala Cys Lys Ala Ser
115 120 125

Phe Lys Arg Lys Ile Gln Ala Asn Ile Glu Tyr Ser Cys Pro Ala Thr
130 135 140

Asn Glu Cys Glu Ile Thr Lys Arg Arg Arg Lys Ser Cys Gln Ala Cys
145 150 155 160

Arg Phe Met Lys Cys Leu Lys Val Gly Met Leu Lys Glu Gly Val Arg
165 170 175

Leu Asp Arg Val Arg Gly Gly Arg Gln Lys Tyr Lys Arg Arg Ile Asp
180 185 190

Ala Glu Asn Ser Pro Tyr Leu Asn Pro Gln Leu Val Gln Pro Ala Lys
195 200 205

Lys Pro Tyr Asn Lys Ile Val Ser His Leu Leu Val Ala Glu Pro Glu
210 215 220

Lys Ile Tyr Ala Met Pro Asp Pro Thr Val Pro Asp Ser Asp Ile Lys
225 230 235 240

Ala Leu Thr Thr Leu Cys Asp Cys Ala Asp Arg Glu Leu Val Val Ile
245 250 255

Ile Gly Trp Ala Lys His Ile Pro Gly Phe Ser Thr Leu Ser Leu Ala
260 265 270

Asp Gln Met Ser Leu Leu Gln Ser Ala Trp Met Glu Ile Leu Ile Leu
275 280 285

Gly Phe Val Tyr Arg Ser Leu Ser Phe Glu Asp Glu Leu Val Tyr Ala
290 295 300

Asp Asp Tyr Ile Met Asp Glu Asp Gln Ser Lys Leu Ala Gly Leu Leu
305 310 315 320

Asp Leu Asn Asn Ala Ile Leu Gln Leu Val Lys Lys Tyr Lys Ser Met

325

330

335

Lys Leu Glu Lys Glu Glu Phe Val Thr Leu Lys Ala Ile Ala Leu Ala
340 345 350

Asn Ser Asp Ser Met His Ile Glu Asp Val Glu Ala Val Gln Lys Leu
355 360 365

Gln Asp Val Leu His Glu Ala Leu Gln Asp Tyr Glu Ala Gly Gln His
370 375 380

Met Glu Asp Pro Arg Arg Ala Gly Lys Met Leu Met Thr Leu Pro Leu
385 390 395 400

Leu Arg Gln Thr Ser Thr Lys Ala Val Gln His Phe Tyr Asn Ile Lys
405 410 415

Leu Glu Gly Lys Val Pro Met His Lys Leu Phe Leu Glu Met Leu Glu
420 425 430

Ala Lys Val Cys
435

<210> 9
<211> 519
<212> PRT
<213> Homo sapiens

<400> 9

Met Gly Leu Glu Met Ser Ser Lys Asp Ser Pro Gly Ser Leu Asp Gly
1 5 10 15

Arg Ala Trp Glu Asp Ala Gln Lys Pro Gln Ser Ala Trp Cys Gly Gly
20 25 30

Arg Lys Thr Arg Val Tyr Ala Thr Ser Ser Arg Arg Ala Pro Pro Ser
35 40 45

Glu Gly Thr Arg Arg Gly Gly Ala Ala Arg Pro Glu Glu Ala Ala Glu
50 55 60

Glu Gly Pro Pro Ala Ala Pro Gly Ser Leu Arg His Ser Gly Pro Leu
65 70 75 80

Gly Pro His Ala Cys Pro Thr Ala Leu Pro Glu Pro Gln Val Thr Ser
85 90 95

Ala Met Ser Ser Gln Val Val Gly Ile Glu Pro Leu Tyr Ile Lys Ala

100

105

110

Glu Pro Ala Ser Pro Asp Ser Pro Lys Gly Ser Ser Glu Thr Glu Thr
115 120 125

Glu Pro Pro Val Ala Leu Ala Pro Gly Pro Ala Pro Thr Arg Cys Leu
130 135 140

Pro Gly His Lys Glu Glu Glu Asp Gly Glu Gly Ala Gly Pro Gly Glu
145 150 155 160

Gln Gly Gly Gly Lys Leu Val Leu Ser Ser Leu Pro Lys Arg Leu Cys
165 170 175

Leu Val Cys Gly Asp Val Ala Ser Gly Tyr His Tyr Gly Val Ala Ser
180 185 190

Cys Glu Ala Cys Lys Ala Phe Phe Lys Arg Thr Ile Gln Gly Ser Ile
195 200 205

Glu Tyr Ser Cys Pro Ala Ser Asn Glu Cys Glu Ile Thr Lys Arg Arg
210 215 220

Arg Lys Ala Cys Gln Ala Cys Arg Phe Thr Lys Cys Leu Arg Val Gly
225 230 235 240

Met Leu Lys Glu Gly Val Arg Leu Asp Arg Val Arg Gly Gly Arg Gln
245 250 255

Lys Tyr Lys Arg Arg Pro Glu Val Asp Pro Leu Pro Phe Pro Gly Pro
260 265 270

Phe Pro Ala Gly Pro Leu Ala Val Ala Gly Gly Pro Arg Lys Thr Ala
275 280 285

Pro Val Asn Ala Leu Val Ser His Leu Leu Val Val Glu Pro Glu Lys
290 295 300

Leu Tyr Ala Met Pro Asp Pro Ala Gly Pro Asp Gly His Leu Pro Ala
305 310 315 320

Val Ala Thr Leu Cys Asp Leu Phe Asp Arg Glu Ile Val Val Thr Ile
325 330 335

Ser Trp Ala Lys Ser Ile Pro Gly Phe Ser Ser Leu Ser Leu Ser Asp
340 345 350

Gln Met Ser Val Leu Gln Ser Val Trp Met Glu Val Leu Val Leu Gly
355 360 365

Val Ala Gln Arg Ser Leu Pro Leu Gln Asp Glu Leu Ala Phe Ala Glu
370 375 380

Asp Leu Val Leu Asp Glu Glu Gly Ala Arg Ala Ala Gly Leu Gly Glu
385 390 395 400

Leu Gly Ala Ala Leu Leu Gln Leu Val Arg Arg Leu Gln Ala Leu Arg
405 410 415

Leu Glu Arg Glu Glu Tyr Val Leu Leu Lys Ala Leu Ala Leu Ala Asn
420 425 430

Ser Asp Ser Val His Ile Glu Asp Ala Glu Ala Val Glu Gln Leu Arg
435 440 445

Glu Ala Leu His Glu Ala Leu Leu Glu Tyr Glu Ala Gly Arg Ala Gly
450 455 460

Pro Gly Gly Gly Ala Glu Arg Arg Arg Ala Gly Arg Leu Leu Leu Thr
465 470 475 480

Leu Pro Leu Leu Arg Gln Thr Ala Gly Lys Val Leu Ala His Phe Tyr
485 490 495

Gly Val Lys Leu Glu Gly Lys Val Pro Met His Lys Leu Phe Leu Glu
500 505 510

Met Leu Glu Ala Met Met Asp
515